ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors
A phase 1/2 trial of ADG126, Pembrolizumab, Bevacizumab, Trifluridine/tipiracil and Fruquintinib in advanced solid tumours, run by Adagene Inc, now recruiting.
Overview
ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors is a phase 1/2 interventional study registered as NCT05405595 by Adagene Inc, with 186 participants planned, started 2022-06-15 and due to reach its primary completion in 2026-10-31. Interventions recorded: ADG126, Pembrolizumab (KEYTRUDA®), Standard of Care (Trifluridine/Tipiracil-Bevacizumab) and Standard of care (Fruquintinib).
Similar pages
not linked directly; found by shared links- TrialS-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors
Shares Bevacizumab, Merck & Co. (MSD), Pembrolizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors
Shares ADG126, Bevacizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Phase I/II, Open-label Study to Investigate the Safety, Tolerability, PK, and Preliminary Efficacy of FB849
Shares Merck & Co. (MSD), Pembrolizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) (Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180)) in Japanese Participants With Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC) or Locally Advanced (LA) Unresectable cSCC (MK-3475A-E39)
Shares Merck & Co. (MSD), Pembrolizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialPhase 1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors
Shares Merck & Co. (MSD), Pembrolizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialABL103 in Combination With Pembrolizumab, With or Without Taxane in Advanced or Metastatic Solid Tumors
Shares Merck & Co. (MSD), Pembrolizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialBC3195 in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
Shares Merck & Co. (MSD), Pembrolizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Study of ASKG915 in Patients With Selected Advanced Solid Tumors.
Shares Fruquintinib, Bevacizumab, Metastatic cancer (cancer that has spread) and the tag pipeline.